Satellite Clinical Trial Sites May Improve Minority Patient Accrual But Challenges Still ExistSeptember 8th 2022
Donna Catamero, ANP-BC, OCN, CCRC, presented on her experience in expanding satellite clinical trial operations during the International Myeloma Society’s 6th Annual Nursing Symposium.
Pivekimab Sunirine Generates Responses in Frontline Blastic Plasmacytoid Dendritic Cell NeoplasmSeptember 5th 2022
Phase 2 findings from the CADENZA trial suggest that pivekimab sunirine may be effective against blastic plasmacytoid dendritic cell neoplasm, a rare and aggressive form of hematologic cancer.
New Virtual Frailty Assessments Seek to Standardize Performance Measures for Older Adults With Blood CancerAugust 27th 2022
Investigators at Dana-Farber Cancer Institute are developing a virtual frailty assessment, which combines both patient-reported outcomes and standardized performance measures.
FDA Gives Pemigatinib Greenlight for FGFR1 Rearranged Myeloid/Lymphoid NeoplasmsAugust 26th 2022
Pemigatinib has received FDA approval for relapsed or refractory myeloid/lymphoid neoplasms and FGFR1 rearrangement. Patients receiving pemigatinib will require monitoring for ocular toxicities and high phosphate levels.
FDA Approves Single-Dose Betibeglogene Autotemcel for Patients With Beta-Thalassemia Who Require RBC TransfusionsAugust 18th 2022
Betibeglogene autotemcel is the first FDA-approved cell-based gene therapy to treat adult and pediatric patients with beta-thalassemia who need routine blood tranfusions.
Nurses Adapt to New Hematology Advances and Approvals in Leukemia TreatmentAugust 8th 2022
Treatments options for various histologies of leukemia are expanding with FDA approvals for drugs such as the combination of ivosidenib/azacitidine and the CAR T-cell therapy brexucabtagene autoleucel.
FDA Schedules ODAC Meetings to Review Pending Drug ApplicationsAugust 6th 2022
The FDA has scheduled 3 sessions for the Oncologic Drugs Advisory Committee to review updates on the new drug application for poziotinib tablets and data for the continued approval of indications for melphalan flufenamide and duvelisib.
Adkins Discusses Benefit of Second-line CAR T-Cell Therapy in Large B-Cell LymphomaAugust 4th 2022
Sherry Adkins, MSN, ANP-C, discusses the significance of incorporating CAR T-cell therapy regimens, such as lisocabtagene autoleucel, into earlier lines of treatment for patients with relapsed/refractory large B-cell lymphoma.
McNally Spotlights Need for Better CIPN Research in Aggressive LymphomasJuly 25th 2022
Gretchen McNally, PhD, ANP-BC, AOCNP, discusses the rationale behind a pilot study which will assess patient reported outcomes for patients with lymphoma who develop chemotherapy-induced peripheral lymphoma.
Kahl Discusses the Future of Maintenance Therapy in Mantel Cell LymphomaJuly 24th 2022
An expert with the Washington University School of Medicine in St Louis outlines the benefit of rituximab, and other maintenance therapies, for patients with mantel cell lymphoma who are in remission.
Addition of Polatuzumab Vedotin to R-CHP Reduces Risk of Disease Progression, Death in DLBCLJuly 23rd 2022
Phase 3 findings from the POLARIX trial showed that the addition of platuzumab vedotin to rituximab, cyclophosphamide, doxorubicin, and prednisone resulted in a 27% reduction in risk of disease progression, relapse, or death for patients with newly diagnosed diffuse large B-cell lymphoma.
Axi-cel Linked To Longer Quality Time Without Toxicity in Patients With R/R LBCLJuly 22nd 2022
A quality time without symptoms of toxicities analysis of the pivotal ZUMA-7 trial found that patients with relapsed or refractory large B-cell lymphoma experienced longer time without toxicity with axicabtagene ciloleucel than with standard of care.
Mosunetuzumab Receives Priority Review Designation for Relapsed/Refractory Follicular LymphomaJuly 22nd 2022
Mosunetuzumab, a CD20 and CD3 T-cell engaging bispecific antibody, received a priority review designation from the FDA for the treatment of patients with relapsed/refractory follicular lymphoma following at least 2 prior systemic therapies.
Ixazomib/Lenalidomide/Dexamethasone Shows Consistent Outcomes in 3 Real-World Analyses of Use for Patients with R/R Multiple MyelomaJuly 21st 2022
A combined analysis of 3 real-world studies assessing the use of ixazomib/lenalidomide/dexamethasone (IRd) in patients with relapsed or refractory multiple myeloma found the patient outcomes to be consistent with original phase 3 findings.